Life-Saving drug offered to children with rare immune disease
NCT ID NCT06003881
Summary
This program provides access to an experimental drug called pozelimab for patients with CHAPLE disease, a rare and potentially life-threatening immune disorder that usually appears in childhood. The main goal is to document the long-term safety of the treatment in these patients. Participants must have a confirmed genetic diagnosis of CHAPLE disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD55-DEFICIENT PROTEIN-LOSING ENTEROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.